Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Dis...
Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: GlobeNewswire
Study Highlights Dagger® Technology Showing that an Optimized CD70 CAR has the Potential to Protect Against Immune Rejection, Enabling Robust Expansion and Persistence of Allogeneic CAR T Cells in Pre-Clinical ModelsDual CD19/CD70 CAR T Cells Rapidly Eliminated B and T Cells in Systemic Lupus Erythematosus (SLE) Models, Halting Autoantibody ProductionPhase 1 RESOLUTION Dose Escalation Rheumatology Basket Trial Actively Enrolling; Initial Data from First Dose Level Expected June 2026 with an Additional Clinical Update Planned for Year-EndALLO-329 Previously Received Three FDA Fast Track Designations for the Treatment of Adult Patients with Lupus, Myositis and Scleroderma SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced the publication of pre-clinical data for ALLO-329 i
Show less
Read more
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- Allogene Therapeutics Announces Pricing of Public Offering of Common StockGlobeNewswire
- Allogene Therapeutics (ALLO) had its price target raised by Argus from $1.60 to $3.85. They now have a "market perform" rating on the stock.MarketBeat
- Allogene Therapeutics (ALLO) had its "market perform" rating reaffirmed by Sanford C. Bernstein.MarketBeat
- Allogene Therapeutics (ALLO) had its price target raised by Citizens Jmp from $5.00 to $8.00. They now have a "market outperform" rating on the stock.MarketBeat
- Allogene Therapeutics (ALLO) had its price target raised by Robert W. Baird from $7.00 to $9.00. They now have an "outperform" rating on the stock.MarketBeat
ALLO
Earnings
- 3/12/26 - Beat
ALLO
Sec Filings
- 4/15/26 - Form 8-K
- 4/15/26 - Form 424B5
- 4/13/26 - Form 424B5
- ALLO's page on the SEC website